Skip to main content

Advertisement

You are viewing the new article page. Let us know what you think. Return to old version

Erratum to: Looking forward to new targeted treatments for chronic spontaneous urticaria

The original article was published in Clinical and Translational Allergy 2017 7:1

Erratum to: Clin Transl Allergy (2017) 7:1 DOI 10.1186/s13601-016-0139-2

Information from the manufacturer of the topical intervention in the GSK2646264 trial outlined in this review [1] indicates that the half-life of the product has not been established with certainty on the available data.

Reference

  1. 1.

    Kocatürk E, Maurer M, Metz M, Grattan C. Looking forward to new targeted treatments for chronic spontaneous urticaria. Clin Transl Allergy. 2017;7:1.

Download references

Author information

Correspondence to Emek Kocatürk.

Additional information

The online version of the original article can be found under doi:10.1186/s13601-016-0139-2.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark